ALS
Sensorion
Stock
Stock
ISIN: FR0012596468
Ticker: ALSEN
FR0012596468
ALSEN
Price
Price
CHART BY
Frequently asked questions
What is Sensorion's market capitalization?
The market capitalization of Sensorion is 188.03M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Sensorion?
Sensorion's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.105. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Sensorion's stock?
Currently, 4 analysts cover Sensorion's stock, with a consensus target price of 2.375. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Sensorion?
Sensorion's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -30.52M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Sensorion?
Sensorion has a free cash flow of -23.54M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Sensorion have, and what sector and industry does it belong to?
Sensorion employs approximately 57 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Major industry.
What is the free float of Sensorion's shares?
The free float of Sensorion is 230.28M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- 188.03M
- EPS (TTM)
- -$0.105
- Free Float
- 230.28M
- EBITDA (TTM)
- -30.52M
- Free Cashflow (TTM)
- -23.54M
Pricing
- 1D span
- $0.651$0.662
- 52W span
- $0.449$1.128
Analyst Ratings
The price target is 2.375 and the stock is covered by 4 analysts.
Buy
4
Hold
0
Sell
0
Information
Sensorion SA is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo, and tinnitus. The company was founded by Christian Chabbert, Gilles Desmadryl, Sylvain Bartolami and Sophie Gaboyard in 2009 and is headquartered in Montpellier, France.
- Employees
- 57
- Industries
- Pharmaceuticals: Major
- Sector
- Health Care
Identifier
- ISIN
- FR0012596468
- Primary Ticker
- ALSEN